FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093582768> ?p ?o ?g. }

• W3093582768 endingPage "S259" @default.
• W3093582768 startingPage "S259" @default.
• W3093582768 abstract "INTRODUCTION: A new tablet bowel prep for colonoscopy has been developed containing poorly absorbed sulfate salts which pull water across the intestinal lumen resulting in copious diarrhea, thereby cleansing the bowel. This study evaluated the safety and efficacy of these oral sulfate tablets (OST) compared to an FDA-approved bowel prep containing PEG3350, electrolytes and ascorbate (PEG-EA). METHODS: 515 adult patients (mean 57 yoa) were enrolled in this single-blind, multi-center study. Patients were assigned either PEG-EA or OST to be administered in a split-dose (PM/AM) regimen starting the evening prior to colonoscopy. PEG-EA was taken according to its approved labeling (1 L of prep solution with 16 oz of additional water per dose). OST patients took 12 tablets per dose with 16 oz of water. Patients drank another 32 oz of water with each dose. Colonoscopies were performed by blinded endoscopists. Cleansing efficacy was evaluated using a traditional 4-point global scale (Excellent/Good/Fair/Poor), similar to that used in pivotal studies of numerous marketed bowel preps. Scores of Good or Excellent were considered a Success. Safety was assessed by spontaneously reported adverse events (AEs), solicited ratings of expected prep symptoms, and laboratory testing. RESULTS: A high rate of cleansing success was seen with OST (92%), which was considered non-inferior to PEG-EA (89%, P < 0.001 using a 10% margin). In addition, the OST procedures rated as Excellent for both the global assessment (66%) and right colon (64%) were significantly higher than PEG-EA (57% and 55%, respectively, P < 0.05). In patients at higher risk of failed prep (constipated, obese, prior failure or opioid users), OST was non-inferior to PEG-EA (90% vs 83%, respectively, P < 0.001). OST prep was well tolerated, with no difference from PEG-EA in spontaneously reported AE rates. Only a small proportion of patients (< 5% for both preps) rated their expected GI symptoms as severe. No clinically significant differences were seen between preps for chemistry and hematology parameters. No serious AEs were reported with OST. CONCLUSION: Sulfate tablets achieved a high level of cleansing in the study, comparable to FDA-approved preps. OST was non-inferior to PEG-EA in this study and achieved significantly more Excellent preps overall and in the right colon. The OST prep was well tolerated, with a similar rate of spontaneously reported AEs to PEG-EA, and a low rate of severe expected GI symptoms." @default.
• W3093582768 created "2020-10-29" @default.
• W3093582768 creator A5004239876 @default.
• W3093582768 creator A5015157882 @default.
• W3093582768 creator A5018781693 @default.
• W3093582768 creator A5056284329 @default.
• W3093582768 creator A5067499088 @default.
• W3093582768 creator A5070573184 @default.
• W3093582768 creator A5074797171 @default.
• W3093582768 date "2020-10-01" @default.
• W3093582768 modified "2023-09-27" @default.
• W3093582768 title "S0519 Comparison of Safety and Efficacy of a New Oral Sulfate-Based Tablet Bowel Preparation Compared to Split Dose PEG-EA" @default.
• W3093582768 doi "https://doi.org/10.14309/01.ajg.0000704124.80292.9b" @default.
• W3093582768 hasPublicationYear "2020" @default.
• W3093582768 type Work @default.
• W3093582768 sameAs 3093582768 @default.
• W3093582768 citedByCount "1" @default.
• W3093582768 countsByYear W30935827682021 @default.
• W3093582768 crossrefType "journal-article" @default.
• W3093582768 hasAuthorship W3093582768A5004239876 @default.
• W3093582768 hasAuthorship W3093582768A5015157882 @default.
• W3093582768 hasAuthorship W3093582768A5018781693 @default.
• W3093582768 hasAuthorship W3093582768A5056284329 @default.
• W3093582768 hasAuthorship W3093582768A5067499088 @default.
• W3093582768 hasAuthorship W3093582768A5070573184 @default.
• W3093582768 hasAuthorship W3093582768A5074797171 @default.
• W3093582768 hasBestOaLocation W30935827681 @default.
• W3093582768 hasConcept C10138342 @default.
• W3093582768 hasConcept C121332964 @default.
• W3093582768 hasConcept C121608353 @default.
• W3093582768 hasConcept C126322002 @default.
• W3093582768 hasConcept C1276947 @default.
• W3093582768 hasConcept C141071460 @default.
• W3093582768 hasConcept C162324750 @default.
• W3093582768 hasConcept C197934379 @default.
• W3093582768 hasConcept C2776476923 @default.
• W3093582768 hasConcept C2778435480 @default.
• W3093582768 hasConcept C2780661987 @default.
• W3093582768 hasConcept C2781112942 @default.
• W3093582768 hasConcept C2781413609 @default.
• W3093582768 hasConcept C526805850 @default.
• W3093582768 hasConcept C54400483 @default.
• W3093582768 hasConcept C71924100 @default.
• W3093582768 hasConcept C90924648 @default.
• W3093582768 hasConceptScore W3093582768C10138342 @default.
• W3093582768 hasConceptScore W3093582768C121332964 @default.
• W3093582768 hasConceptScore W3093582768C121608353 @default.
• W3093582768 hasConceptScore W3093582768C126322002 @default.
• W3093582768 hasConceptScore W3093582768C1276947 @default.
• W3093582768 hasConceptScore W3093582768C141071460 @default.
• W3093582768 hasConceptScore W3093582768C162324750 @default.
• W3093582768 hasConceptScore W3093582768C197934379 @default.
• W3093582768 hasConceptScore W3093582768C2776476923 @default.
• W3093582768 hasConceptScore W3093582768C2778435480 @default.
• W3093582768 hasConceptScore W3093582768C2780661987 @default.
• W3093582768 hasConceptScore W3093582768C2781112942 @default.
• W3093582768 hasConceptScore W3093582768C2781413609 @default.
• W3093582768 hasConceptScore W3093582768C526805850 @default.
• W3093582768 hasConceptScore W3093582768C54400483 @default.
• W3093582768 hasConceptScore W3093582768C71924100 @default.
• W3093582768 hasConceptScore W3093582768C90924648 @default.
• W3093582768 hasIssue "1" @default.
• W3093582768 hasLocation W30935827681 @default.
• W3093582768 hasLocation W30935827682 @default.
• W3093582768 hasOpenAccess W3093582768 @default.
• W3093582768 hasPrimaryLocation W30935827681 @default.
• W3093582768 hasRelatedWork W1972411065 @default.
• W3093582768 hasRelatedWork W2021416544 @default.
• W3093582768 hasRelatedWork W2034211994 @default.
• W3093582768 hasRelatedWork W2045439269 @default.
• W3093582768 hasRelatedWork W2047226612 @default.
• W3093582768 hasRelatedWork W2061627592 @default.
• W3093582768 hasRelatedWork W2395827093 @default.
• W3093582768 hasRelatedWork W2955541446 @default.
• W3093582768 hasRelatedWork W3143614914 @default.
• W3093582768 hasRelatedWork W4384561793 @default.
• W3093582768 hasVolume "115" @default.
• W3093582768 isParatext "false" @default.
• W3093582768 isRetracted "false" @default.
• W3093582768 magId "3093582768" @default.
• W3093582768 workType "article" @default.